SLC5A2 and hydrops fetalis: Sodium–glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin and empagliflozin, significantly reduce renal disease progression, HF hospitalizations, and mortality in patients with and without diabetes [25,26,27].